Lisdexamfetamine May Improve Cognitive Difficulties in Menopausal Women

Ok, this has nothing to do with stroke but someone has to connect the dots. Lots of stroke patients have cognitive difficulties, would this help any of them? Your doctor should be able to analyze and answer simple questions like this. Or setup clinical trials to find the answer. If your doctor is not doing this type of stuff your stroke department head needs to have such performance goals set by the hospital president. Once again you need to call the hospital president and see what goals are required to be met by the stroke department. This is NOT going to occur without YOU pushing for it. So call the president, your stroke department has been failing for 30 years, why let it fail even longer and endanger your children and grandchildren? 
http://dgnews.docguide.com/lisdexamfetamine-may-improve-cognitive-difficulties-menopausal-women?
Women experiencing difficulty with time management, attention, organization, memory, and problem solving related to menopause may find improvement with a drug already being used to treat attention-deficit/hyperactivity disorder (ADHD).
The study, published online today in the journal Psychopharmacology, is the first to show that lisdexamfetamine (LDX) improved subjective and objective measures of cognitive decline commonly experienced in menopausal women.
“Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,” said lead author C. Neill Epperson, MD, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. “There are approximately 90 million post-menopausal women living in the United States alone, and with the average age of onset occurring at 52, the great majority of those women will live in the postmenopausal state for at least one-third of their lives. Therefore, promoting healthy cognitive aging among menopausal women should be a major public health goal.”
The researchers administered a once-daily dose of LDX for 4 weeks to 32 healthy women aged 45 to 60 years experiencing difficulties with executive functions as a result of mid-life onset menopause, and as measured using the Brown Attention Deficit Disorder Scale (BADDS). All participants served as their own controls by being randomly assigned to cross-over to a placebo for an additional 4 weeks. None of the women in the study were diagnosed with ADHD.
The researchers found a 41% overall improvement in executive functions for women receiving LDX, compared with a 17% improvement when taking placebo. There were also significant improvements in 4 out of the 5 subscales for women taking LDX: organization and motivation for work; attention and concentration; alertness, effort, and processing speed; and working memory and accessing recall.
While psychostimulants such as LDX are primarily marketed for the treatment of ADHD, they have been successful in treating cognitive complaints in some patients including postmenopausal women.
“Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,” said Dr. Epperson. “It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.”
Source: University of Pennsylvania School of Medicine